AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12834321 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10770466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose haloperidol with dose reduction to achieve target plasma level of 10 ng/mL over 12 weeks
Number of subjects: 23
Study 10770466 — intervention group
Group type: COMPARATOR
Intervention: Control group maintained original high-dose haloperidol treatment
Number of subjects: 23
Study 9310019 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid treatment, budesonide 400 micrograms twice daily
Number of subjects: 61
Study 9310019 — intervention group
Group type: COMPARATOR
Intervention: Chronic asthma
Number of subjects: 61
Study 9310019 — intervention group
Group type: COMPARATOR
Intervention: Seasonal asthma
Number of subjects: 61
Study 8167083 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide in the anesthetic mixture
Number of subjects: 44
Study 8167083 — intervention group
Group type: COMPARATOR
Intervention: No nitrous oxide in the anesthetic mixture
Number of subjects: 44
Study 2944432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide anaesthesia (Group A)
Number of subjects: 87
Study 2944432 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B, no nitrous oxide)
Number of subjects: 87
Study 31669136 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of GIP (50 pmol/kg body weight at 30 and 120 min)
Number of subjects: 0
Study 31669136 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of GIP (2 pmol.kg-1.min-1 from 30 to 180 min)
Number of subjects: 0
Study 31669136 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus administration of GIP
Number of subjects: 0
Study 31669136 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of GIP
Number of subjects: 0
Study 30545134 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (3000 IU/day)
Number of subjects: 36
Study 30545134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin D3 supplementation)
Number of subjects: 36
Study 27039386 — intervention group
Group type: EXPERIMENTAL
Intervention: E7820 50 mg BID
Number of subjects: 41
Study 27039386 — intervention group
Group type: EXPERIMENTAL
Intervention: E7820 60 mg BID
Number of subjects: 41
Study 27039386 — intervention group
Group type: EXPERIMENTAL
Intervention: E7820 100 mg QD
Number of subjects: 41
Study 25208796 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) therapy, 15 minutes, 3 times per week for 7 months
Number of subjects: 104
Study 25208796 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumping Intervention (JIN), 3 times per week for 8 months
Number of subjects: 104
Study 25208796 — intervention group
Group type: COMPARATOR
Intervention: Normal swimming training (control group)
Number of subjects: 104
Study 22719814 — intervention group
Group type: EXPERIMENTAL
Intervention: BPN/NLX
Number of subjects: 94
Study 22719814 — intervention group
Group type: COMPARATOR
Intervention: Non-BPN/NLX
Number of subjects: 94
Study 20047610 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reduction of corticosteroid dose (prednisone 5 mg every other day for 12 months)
Number of subjects: 83
Study 20047610 — intervention group
Group type: COMPARATOR
Intervention: Regular-dose corticosteroid maintenance (prednisone progressively reduced from days 8 to 90, then maintained for 12 months)
Number of subjects: 83
Study 18692612 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 1A (Dienogest dosage not specified)
Number of subjects: 395
Study 18692612 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2A (Dienogest dosage not specified)
Number of subjects: 395
Study 18692612 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2B (Increased Dienogest dosage)
Number of subjects: 395
Study 18692612 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen 2C (Increased Dienogest dosage)
Number of subjects: 395
Study 15721696 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic LASIK
Number of subjects: 54
Study 15721696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperopic LASIK
Number of subjects: 54
Study 11936481 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1a (IFNbeta-1a)
Number of subjects: 533
Study 10528291 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 min acquisition time for scintimammography
Number of subjects: 0
Study 10528291 — intervention group
Group type: COMPARATOR
Intervention: 10 min acquisition time for scintimammography
Number of subjects: 0
Study 7860310 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed group (cumulative radiation doses of about 500 mSv or more)
Number of subjects: 36
Study 7860310 — intervention group
Group type: COMPARATOR
Intervention: Unexposed group (cumulative radiation doses less than 50 mSv)
Number of subjects: 36
Study 1816543 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentin adhesives
Number of subjects: 2
Study 1816543 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive formulated with glycidyl methacrylate
Number of subjects: 2
Study 1816543 — intervention group
Group type: COMPARATOR
Intervention: Composite restorative materials without adhesives
Number of subjects: 2
Study 7051507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin, 250 mg, qid for 7-14 days
Number of subjects: 95
Study 7051507 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid, 1 Gm, qid for 7-14 days
Number of subjects: 95
Study 7051507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin
Number of subjects: 95
Study 7051507 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 95
Study 31056655 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid-rich natural cocoa (F)
Number of subjects: 134
Study 28418028 — intervention group
Group type: EXPERIMENTAL
Intervention: New algorithm for predicting advanced proximal neoplasia (APN) based on distal colonoscopic findings.
Number of subjects: 3889
Study 28418028 — intervention group
Group type: COMPARATOR
Intervention: High Risk (HR) group based on a cut-off score of 2.
Number of subjects: 3889
Study 28418028 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up colonoscopies required to detect APN.
Number of subjects: 3889
Study 27238963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 3mg every 4 weeks
Number of subjects: 300
Study 27238963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 9mg every 4 weeks
Number of subjects: 300
Study 27238963 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone CR twice-daily
Number of subjects: 300
Study 27238963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 23674935 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil (150 mg/day)
Number of subjects: 69
Study 23674935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 23674935 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment after 6 weeks
Number of subjects: 69
Study 23674935 — intervention group
Group type: COMPARATOR
Intervention: Armodafinil vs Placebo
Number of subjects: 69
Study 22320027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan and quinidine (DMQ) at doses of 0, 30, and 60 mg
Number of subjects: 9
Study 22320027 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg DMQ)
Number of subjects: 9
Study 18694599 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 83
Study 18694599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 83
Study 17696825 — intervention group
Group type: EXPERIMENTAL
Intervention: APC8015 (Provenge®), an immunotherapeutic consisting of autologous dendritic cells pulsed ex vivo with PA2024.
Number of subjects: 0
Study 15459950 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive tablets with natural active agents
Number of subjects: 248
Study 15459950 — intervention group
Group type: COMPARATOR
Intervention: Plain tablets (control)
Number of subjects: 248
Study 11331049 — intervention group
Group type: EXPERIMENTAL
Intervention: Realtime teledermatology consultation
Number of subjects: 274
Study 11331049 — intervention group
Group type: COMPARATOR
Intervention: Conventional hospital outpatient consultation
Number of subjects: 274
Study 11331049 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity analysis in urban areas
Number of subjects: 274
Study 11331049 — intervention group
Group type: COMPARATOR
Intervention: Sensitivity analysis in rural areas
Number of subjects: 274
Study 9571269 — intervention group
Group type: EXPERIMENTAL
Intervention: DAILIES(TM) daily disposable soft lenses for 8 hours
Number of subjects: 20
Study 8027750 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided needle device
Number of subjects: 41
Study 8027750 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard technique)
Number of subjects: 41
Study 2644752 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (3 mg/kg bolus injection)
Number of subjects: 30
Study 2644752 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 31783936 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle intervention including motivational text messages for 8 weeks
Number of subjects: 21
Study 31783936 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle intervention
Number of subjects: 21
Study 31783936 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 21
Study 30900413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Number of subjects: 196
Study 30900413 — intervention group
Group type: COMPARATOR
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 196
Study 30900413 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 196
Study 27815700 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoplant (diosmin, coumarin glycosides, and Centella asiatica) for 30 days post-SA
Number of subjects: 182
Study 27815700 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days post-SA
Number of subjects: 182
Study 26658275 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback regarding naturalistic driving record and CPAP compliance
Number of subjects: 66
Study 26658275 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 66
Study 26658275 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback
Number of subjects: 66
Study 23398927 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 39
Study 23398927 — intervention group
Group type: COMPARATOR
Intervention: Text (TX)
Number of subjects: 39
Study 23398927 — intervention group
Group type: COMPARATOR
Intervention: Audio (AU)
Number of subjects: 39
Study 23398927 — intervention group
Group type: COMPARATOR
Intervention: Video (VD)
Number of subjects: 39
Study 23398927 — intervention group
Group type: EXPERIMENTAL
Intervention: Technological breakdowns in VR
Number of subjects: 39
Study 23398927 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence experience (SUS scores)
Number of subjects: 39
Study 21442218 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing cue present throughout the trial
Number of subjects: 0
Study 21442218 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing cue present with directional cue
Number of subjects: 0
Study 21442218 — intervention group
Group type: COMPARATOR
Intervention: Directional cue without timing cue
Number of subjects: 0
Study 18171629 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial-basilic AVF (BB-AVF)
Number of subjects: 61
Study 18171629 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic forearm loop AVF
Number of subjects: 61
Study 16813738 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-sensitizing treatment strategies
Number of subjects: 0
Study 16813738 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-providing treatment strategies
Number of subjects: 0
Study 14517164 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 200 mg daily
Number of subjects: 202
Study 14517164 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 40 mg daily
Number of subjects: 202
Study 14517164 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 200 mg and Enalapril 10 mg daily
Number of subjects: 202
Study 14517164 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone
Number of subjects: 202
Study 14517164 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 202
Study 14517164 — intervention group
Group type: COMPARATOR
Intervention: Eplerenone/Enalapril
Number of subjects: 202
Study 10996360 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of the EcoRI restriction site (L4154) of the apo B gene
Number of subjects: 214
Study 10996360 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL S447stop mutation
Number of subjects: 214
Study 10996360 — intervention group
Group type: EXPERIMENTAL
Intervention: LPL N291S mutation
Number of subjects: 214
Study 10996360 — intervention group
Group type: EXPERIMENTAL
Intervention: S291 allele
Number of subjects: 214
Study 10996360 — intervention group
Group type: COMPARATOR
Intervention: apo E and CETP genotypes
Number of subjects: 214
Study 8869672 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg/kg
Number of subjects: 20
Study 8869672 — intervention group
Group type: COMPARATOR
Intervention: Pipecuronium 0.1 mg/kg
Number of subjects: 20
Study 1642124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright dawn simulation (1700 lx) from 0400 to 0600
Number of subjects: 7
Study 1642124 — intervention group
Group type: COMPARATOR
Intervention: Standard bright morning light therapy (1700 lx) from 0600 to 0800
Number of subjects: 7
Study 7198288 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive treatment (bed rest in febrile stage, avoiding activities that promote headache)
Number of subjects: 39
Study 7198288 — intervention group
Group type: COMPARATOR
Intervention: Liberal treatment (encouraged to resume daily life as soon as possible)
Number of subjects: 39
Study 29923314 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR 102681 (cholecystokinin-B antagonist)
Number of subjects: 16
Study 27664969 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based reporting group
Number of subjects: 40
Study 27664969 — intervention group
Group type: COMPARATOR
Intervention: standard-of-care group
Number of subjects: 40
Study 26335229 — intervention group
Group type: EXPERIMENTAL
Intervention: Video conferencing
Number of subjects: 50
Study 26335229 — intervention group
Group type: COMPARATOR
Intervention: Cellular communication
Number of subjects: 50
Study 23694919 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine stress thallium-201 myocardial perfusion imaging
Number of subjects: 41
Study 23694919 — intervention group
Group type: COMPARATOR
Intervention: Exercise stress thallium-201 myocardial perfusion imaging
Number of subjects: 41
Study 21444145 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-led (IL) training
Number of subjects: 120
Study 21444145 — intervention group
Group type: COMPARATOR
Intervention: Self-learning (SL) station training
Number of subjects: 120
Study 19546404 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal brachytherapy (VBT)
Number of subjects: 427
Study 19546404 — intervention group
Group type: COMPARATOR
Intervention: External-beam radiotherapy (EBRT)
Number of subjects: 427
Study 19546404 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 427
Study 17298579 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell volume-based guideline
Number of subjects: 0
Study 17298579 — intervention group
Group type: COMPARATOR
Intervention: Haemoglobin-based protocol
Number of subjects: 0
Study 15323600 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 199
Study 15323600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 11584088 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly vitamin A and iron supplementation (4800 retinol equivalents (RE) + 120 mg Fe as FeSO(4) + 500 microg folic acid)
Number of subjects: 170
Study 11584088 — intervention group
Group type: COMPARATOR
Intervention: Weekly iron supplementation (120 mg Fe as FeSO(4) + 500 microg folic acid)
Number of subjects: 170
Study 11584088 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly vitamin A and iron supplementation
Number of subjects: 170
Study 11584088 — intervention group
Group type: COMPARATOR
Intervention: Weekly iron supplementation
Number of subjects: 170
Study 9564665 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-agonist therapy for three months
Number of subjects: 0
Study 9564665 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative treatment for three months
Number of subjects: 0
Study 9564665 — intervention group
Group type: COMPARATOR
Intervention: Surgical approaches (laparoscopy or minilaparoscopy)
Number of subjects: 0
Study 7868106 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 49
Study 7868106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 2671402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HSL, Na 250 mEq/L, 514 mOsm)
Number of subjects: 51
Study 2671402 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR, Na 130 mEq/L, 268 mOsm)
Number of subjects: 51
Study 618025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low concentrations of noxious gases from machinery and explosives
Number of subjects: 1178
Study 618025 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard questionnaire (E.C.S.C. bronchitis/emphysema questionnaire) and clinical examination
Number of subjects: 1178
Study 618025 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous blood sample for blood CO determination
Number of subjects: 1178
Study 31796986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (IL-6 receptor antagonist) 8 mg/kg every 4 weeks
Number of subjects: 52
Study 31796986 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (DPP-4 inhibitor) 100 mg daily
Number of subjects: 52
Study 31796986 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion every 4 weeks and placebo pill once daily)
Number of subjects: 52
Study 31174168 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarette
Number of subjects: 128
Study 31174168 — intervention group
Group type: COMPARATOR
Intervention: Non-nicotine e-cigarette with instructions indicating nicotine
Number of subjects: 128
Study 31174168 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarette with complementary instructions
Number of subjects: 128
Study 27079636 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (1×10^9 CFU containing seven strains of lactic acid-producing bacteria) every 12 hours for six weeks
Number of subjects: 65
Study 27079636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsule)
Number of subjects: 65
Study 25727879 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartNetCare-HF (HNC)
Number of subjects: 706
Study 23812094 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg per day
Number of subjects: 422
Study 23812094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 21785368 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based health and leadership development program
Number of subjects: 145
Study 21785368 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 145
Study 19031167 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 67
Study 19031167 — intervention group
Group type: COMPARATOR
Intervention: Placebo Laser
Number of subjects: 67
Study 17697065 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.1 u/kg)
Number of subjects: 19
Study 17697065 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (0.1 u/kg)
Number of subjects: 19
Study 15318285 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyriax approach (CYR) - deep friction massage and mobilisation exercises three times weekly
Number of subjects: 40
Study 15318285 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy (PT) - daily physical therapy including hot pack and short wave diathermy application
Number of subjects: 40
Study 12441023 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonergic antidepressants (first-line treatment)
Number of subjects: 0
Study 12441023 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) during symptomatic luteal phase
Number of subjects: 0
Study 12441023 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release formulation of fluoxetine (taken two times during the menstrual cycle)
Number of subjects: 0
Study 12441023 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptives
Number of subjects: 0
Study 12441023 — intervention group
Group type: EXPERIMENTAL
Intervention: New contraceptive formulation
Number of subjects: 0
Study 12441023 — intervention group
Group type: COMPARATOR
Intervention: Progesterone and progestins
Number of subjects: 0
Study 9789122 — intervention group
Group type: EXPERIMENTAL
Intervention: MLT plus aloe vera tincture (1 ml twice/day)
Number of subjects: 50
Study 9789122 — intervention group
Group type: COMPARATOR
Intervention: MLT alone (20 mg/day orally in the dark period)
Number of subjects: 50
Study 8020904 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunts (TIPS)
Number of subjects: 30
Study 8020904 — intervention group
Group type: COMPARATOR
Intervention: Sclerotherapy (control)
Number of subjects: 30
Study 2553335 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg 4-times daily
Number of subjects: 202
Study 2553335 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate 0.1 mg 4-times daily
Number of subjects: 202
Study 2553335 — intervention group
Group type: COMPARATOR
Intervention: Placebo 2 puffs 4-times daily
Number of subjects: 202
Study 793481 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole at a dosage of 2.5 mg/kg/day
Number of subjects: 0
Study 793481 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0